en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2024
vol. 99
 
Share:
Send email
Share:
abstract:
Review paper

Lactobacillus rhamnosus for treating irritable bowel syndrome in children – a systematic review with meta-analysis

Joanna Tarnoruda
1
,
Marek Ruszczyński
1
,
Jakub Żółkiewicz
2
,
Luiza Sulej
1
,
Barbara Bożek
1
,
Aleksandra Hoffmann
1

  1. Department of Paediatrics, Medical University of Warsaw Children’s Hospital, Warsaw, Poland
  2. Department of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland
Pediatr Pol 2024; 99 (1): 53-60
DOI: https://doi.org/10.5114/polp.2024.136009
Online publish date: 2024/03/09
View full text Get citation
 
PlumX metrics:
The objective of the study was to systematically assess whether the oral probiotic Lactobacillus rhamnosus (LGG) improves symptoms of irritable bowel syndrome in children. Four randomised clinical trials met the inclusion criteria, a total of 252 patients. Success of treatment was reported in 50 out of 82 patients (58.82%) from the LGG group, compared with 28 from 82 (34.14%) in the placebo group (p = 0.05). The number of pain episodes was lower in the LGG group compared with the placebo group (n = 117, 95% CI: 1.50 [–2.03; –0.97], p < 0.05). The use of LGG resulted in a decrease in the perception of pain intensity in the study population overall (n = 219, 95% CI: –0.61 [–1.13; –0.09], p < 0.05). A higher dosage of LGG was less effective than a lower dosage in improving the overall treatment success (p = 0.05). The dosage of LGG was not statistically significant in improving pain severity (p = 0.12).
keywords:

Lactobacillus rhamnosus, microbiota, probiotic, irritable bowel syndrome